Sign up
Pharma Capital

Humanigen teams up with Kite to treat a type of lymphoma cancer

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based biotech has forged a clinical collaboration with Gilead Sciences Inc's (NASDAQ:GILD) subsidiary Kite, to study its therapy lenzilumab, with Kite's drug called Yescarta in patients suffering with certain forms of lymphoma cancer.

Durrant says he expects this Phase 1/2 study to begin by the end of 2019.

 

View full HGEN profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.